Dallas, Texas 04/24/2014 (FINANCIALSTRENDS) – Celldex Therapeutics, Inc. (NASDAQ:CLDX) was initiated by Bank of America for Phase I study of CDX-1401. This will treat solid tumors, which also includes follow-up of patients and news of this stock has been published in Science Translational Medicine.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been demonstrating technology for robust antibody and T-cell responses. There been evidence of benefits by patients for advanced cancer. The company proposes that by using the CDX-1401, will now prepare patients for better treatment for such advanced cancers by the use of CDX-1401. The drug will show better therapy for checkpoint inhibitors.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) holds a market capital of $1.31billion.The stock has a price range of$15.99and $14.59 along with 52week price range of $11.34 as well as $38.84. The shares of this stock opened at $15.93. EPSis-1.02. Outstanding shares for this stock are 89.63million.Beta is 2.41.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) in recent times has stock institutional ownership of the range 88.50%, with the insider ownership in the range of 0.10%.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) in recent times has been in competition with PFE Inc., with GlaxoSmithKline as well as NorthWestBiothermal, along with BMY. The other participants include AgenusInc, besides Amgen Inc as well.
The company has been involved in the development of therapies which will offer relief from such medical conditions as cancer as well as a range of diseases which are in the range of difficult to treat diseases.
The drug candidate will now allow the company to offer a range of immunotherapeutic vaccine. Such vaccines are found to be of special use, targeting treatment of certain type is of cancer. The drug candidate will also include such as the drugs as CDX-110, CDX-011, CDX-1127 and CDX-110. These will also help in the treatment of epidermal growth of factor as well as receptor variant III.